Lupin has decided to shift its focus on formulating respiratory inhalers by incorporating a propellant with near-zero global warming potential (GWP).

This initiative aims to provide patients with pressurised metered dose inhalers (pMDIs) that maintain the same efficacy and safety, while significantly reducing their environmental impact. This is aligned to the regulations in Europe and Lupin’s commitment to reducing its carbon footprint.

Richard Dekhuijzen, em, Professor of Pulmonology at the Radboud university medical center in Nijmegen, the Netherland said, “The development of inhalers with near-zero global warming potential serves two major objectives: firstly, a maximal reduction of their environmental impact, and secondly, as important, keeping these medications available for those patients who really need these types of inhalers since they are unable to use dry powder inhalers.”

Vinita Gupta, Chief Executive Officer, Lupin said, “We are committed to making a positive impact in the lives of asthma patients worldwide. Our focus is on patient-centric sustainable healthcare innovation, ensuring that those who receive our pMDIs have reliable access to effective treatments with minimal impact to the environment.”

At Lupin, innovation forms the cornerstone of all their initiatives, and the company relentlessly pursue excellence through continuous improvements in all our projects, processes, and products. In the respiratory category, their strategy includes the inhalation portfolio with accelerated development of pipeline products and green propellant development programs for early success.

The company is committed to addressing environmental challenges impacting our patients and communities and actively pursue relevant initiatives for its respiratory solutions. They are working towards replacing standard propellants with near-zero (GWP) in its inhaler products, which will be fundamental to further establishing their position as a responsible pharmaceutical company.